<?xml version='1.0' encoding='UTF-8'?>
<extracted-tables-set><pmcid>8285494</pmcid><all-ids><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" pub-id-type="pmid">34272398</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" pub-id-type="pmc">8285494</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" pub-id-type="publisher-id">205</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" pub-id-type="doi">10.1038/s41531-021-00205-7</article-id></all-ids><extracted-table><table-id>Tab1</table-id><table-label>Table 1</table-label><table-caption>Demographic and clinical characteristics of the studied groups.</table-caption><original-table><table-wrap xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" id="Tab1"><label>Table 1</label><caption><p>Demographic and clinical characteristics of the studied groups.</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Variable</th><th>PD-ICD (<italic>n</italic> = 21)</th><th>PD-noICD (<italic>n</italic> = 33)</th><th>HCs (<italic>n</italic> = 37)</th><th><italic>p</italic></th><th>Post hoc (Bonferroni)</th></tr></thead><tbody><tr><td>Age (y)</td><td>59.0 ± 9.6</td><td>61.7 ± 9.3</td><td>62.0 ± 5.6</td><td>0.378<sup>b</sup></td><td/></tr><tr><td>Gender (M/F)</td><td>12/9</td><td>20/13</td><td>25/12</td><td>0.700<sup>a</sup></td><td/></tr><tr><td>Education (y)</td><td>11.4 ± 3.1</td><td>10.3 ± 3.3</td><td>12.2 ± 3.8</td><td>0.085<sup>c</sup></td><td/></tr><tr><td>Disease duration (y)</td><td>9.0 ± 5.2</td><td>7.1 ± 3.0</td><td>—</td><td>0.241<sup>d</sup></td><td/></tr><tr><td>Age at onset (y)</td><td>50.9 ± 10.1</td><td>54.2 ± 9.7</td><td>—</td><td>0.235<sup>e</sup></td><td/></tr><tr><td>Affected side at onset right% (n)</td><td>47.6% (10)</td><td>42.4% (14)</td><td>—</td><td>0.708<sup>a</sup></td><td/></tr><tr><td>UPDRS part 3</td><td>20.3 ± 14.2</td><td>18.5 ± 11.3</td><td>—</td><td>0.518<sup>d</sup></td><td/></tr><tr><td>H-Y stage</td><td>2.3 ± 0.7</td><td>2.2 ± 0.6</td><td>—</td><td>0.580<sup>d</sup></td><td/></tr><tr><td>LEDD<sub>TOTAL</sub> (mg)</td><td>770.7 ± 310.8</td><td>636.1 ± 271.5</td><td>—</td><td>0.085<sup>d</sup></td><td/></tr><tr><td>LEDD<sub>DA</sub> (mg)</td><td>90.5 ± 57.4</td><td>68.6 ± 50.7</td><td>—</td><td>0.150<sup>e</sup></td><td/></tr><tr><td>DA %</td><td>85.70%</td><td>78.50%</td><td>—</td><td>0.523<sup>a</sup></td><td/></tr><tr><td>QUIP-RS total score</td><td>13.0 ± 5.9</td><td>0</td><td>—</td><td>&lt;0.0001<sup>d, ***</sup></td><td/></tr><tr><td>BIS</td><td>33.1 ± 15.6</td><td>29.7 ± 15.3</td><td>—</td><td>0.495<sup>d</sup></td><td/></tr><tr><td>MMSE</td><td>28.3 ± 1.1</td><td>28.0 ± 1.5</td><td>29.1 ± 0.9</td><td>0.002<sup>c, **</sup></td><td>PD-ICD &lt; HC (<italic>p</italic> = 0.015) PD-noICD &lt; HC (<italic>p</italic> = 0.006)</td></tr><tr><td>HAMA</td><td>14.0 ± 8.9</td><td>11.2 ± 6.1</td><td>2.3 ± 3.3</td><td>&lt;0.0001<sup>c, ***</sup></td><td>PD-ICD &lt; HC (<italic>p</italic> &lt; 0.0001) PD-noICD &lt; HC (<italic>p</italic> &lt; 0.0001)</td></tr><tr><td>HAMD-24</td><td>12.6 ± 8.2</td><td>9.5 ± 7.0</td><td>1.7 ± 2.5</td><td>&lt;0.0001<sup>c, ***</sup></td><td>PD-ICD &lt; HC (<italic>p</italic> &lt; 0.0001) PD-noICD &lt; HC (<italic>p</italic> &lt; 0.0001)</td></tr><tr><td>FAB</td><td>16.2 ± 2.0</td><td>16.4 ± 2.5</td><td>17.0 ± 1.3</td><td>0.232<sup>c</sup></td><td/></tr></tbody></table><table-wrap-foot><p>Values are presents as the mean ± standard deviation.</p><p><italic>PD</italic> Parkinson’s Disease, <italic>ICD</italic> impulse control disorders, <italic>HCs</italic> healthy controls, <italic>M</italic> male, <italic>F</italic> female, <italic>y</italic> year, <italic>UPDRS</italic> Unified Parkinson’s disease rating scale, <italic>H-Y stage</italic> Hoehn and yahr clinical rating scale, <italic>LEDD</italic><sub><italic>TOTAL</italic></sub> total levodopa equivalent daily dose, <italic>LEDD</italic><sub><italic>DA</italic></sub> levodopa equivalent daily dose of dopamine agonist, <italic>DA</italic> dopamine agonist, <italic>QUIP-RS</italic> Questionnaire for Impulsive Compulsive Disorders in Parkinson’s Disease-Rating Scale, <italic>BIS</italic> Barratt Impulsiveness Scale, <italic>MMSE</italic> Mini Mental State Examination, <italic>HAMA</italic> Hamilton Anxiety Scale, <italic>HAMD-24</italic> Hamilton Depression Scale-24, <italic>FAB</italic> Frontal Assessment Battery.</p><p><sup>a</sup>Chi-square test.</p><p><sup>b</sup>One-way ANOVA.</p><p><sup>c</sup>Kruskal-Wallis.</p><p><sup>d</sup>Mann-Whitney U.</p><p><sup>e</sup>Two-sample t-test.</p><p>*<italic>p</italic> &lt; 0.05, **<italic>p</italic> &lt; 0.01, ***<italic>p</italic> &lt; 0.001.</p></table-wrap-foot></table-wrap></original-table><transformed-table>Table 1<div xmlns="http://www.w3.org/1999/xhtml" class="caption">Demographic and clinical characteristics of the studied groups.</div><div xmlns="http://www.w3.org/1999/xhtml" class="table"><table frame="hsides" rules="groups"><thead><tr><th>Variable</th><th>PD-ICD (n = 21)</th><th>PD-noICD (n = 33)</th><th>HCs (n = 37)</th><th>p</th><th>Post hoc (Bonferroni)</th></tr></thead><tbody><tr><td>Age (y)</td><td>59.0 ± 9.6</td><td>61.7 ± 9.3</td><td>62.0 ± 5.6</td><td>0.378b</td><td/></tr><tr><td>Gender (M/F)</td><td>12/9</td><td>20/13</td><td>25/12</td><td>0.700a</td><td/></tr><tr><td>Education (y)</td><td>11.4 ± 3.1</td><td>10.3 ± 3.3</td><td>12.2 ± 3.8</td><td>0.085c</td><td/></tr><tr><td>Disease duration (y)</td><td>9.0 ± 5.2</td><td>7.1 ± 3.0</td><td>—</td><td>0.241d</td><td/></tr><tr><td>Age at onset (y)</td><td>50.9 ± 10.1</td><td>54.2 ± 9.7</td><td>—</td><td>0.235e</td><td/></tr><tr><td>Affected side at onset right% (n)</td><td>47.6% (10)</td><td>42.4% (14)</td><td>—</td><td>0.708a</td><td/></tr><tr><td>UPDRS part 3</td><td>20.3 ± 14.2</td><td>18.5 ± 11.3</td><td>—</td><td>0.518d</td><td/></tr><tr><td>H-Y stage</td><td>2.3 ± 0.7</td><td>2.2 ± 0.6</td><td>—</td><td>0.580d</td><td/></tr><tr><td>LEDDTOTAL (mg)</td><td>770.7 ± 310.8</td><td>636.1 ± 271.5</td><td>—</td><td>0.085d</td><td/></tr><tr><td>LEDDDA (mg)</td><td>90.5 ± 57.4</td><td>68.6 ± 50.7</td><td>—</td><td>0.150e</td><td/></tr><tr><td>DA %</td><td>85.70%</td><td>78.50%</td><td>—</td><td>0.523a</td><td/></tr><tr><td>QUIP-RS total score</td><td>13.0 ± 5.9</td><td>0</td><td>—</td><td>&lt;0.0001d, ***</td><td/></tr><tr><td>BIS</td><td>33.1 ± 15.6</td><td>29.7 ± 15.3</td><td>—</td><td>0.495d</td><td/></tr><tr><td>MMSE</td><td>28.3 ± 1.1</td><td>28.0 ± 1.5</td><td>29.1 ± 0.9</td><td>0.002c, **</td><td>PD-ICD &lt; HC (p = 0.015) PD-noICD &lt; HC (p = 0.006)</td></tr><tr><td>HAMA</td><td>14.0 ± 8.9</td><td>11.2 ± 6.1</td><td>2.3 ± 3.3</td><td>&lt;0.0001c, ***</td><td>PD-ICD &lt; HC (p &lt; 0.0001) PD-noICD &lt; HC (p &lt; 0.0001)</td></tr><tr><td>HAMD-24</td><td>12.6 ± 8.2</td><td>9.5 ± 7.0</td><td>1.7 ± 2.5</td><td>&lt;0.0001c, ***</td><td>PD-ICD &lt; HC (p &lt; 0.0001) PD-noICD &lt; HC (p &lt; 0.0001)</td></tr><tr><td>FAB</td><td>16.2 ± 2.0</td><td>16.4 ± 2.5</td><td>17.0 ± 1.3</td><td>0.232c</td><td/></tr></tbody></table></div>Values are presents as the mean ± standard deviation.PD Parkinson’s Disease, ICD impulse control disorders, HCs healthy controls, M male, F female, y year, UPDRS Unified Parkinson’s disease rating scale, H-Y stage Hoehn and yahr clinical rating scale, LEDDTOTAL total levodopa equivalent daily dose, LEDDDA levodopa equivalent daily dose of dopamine agonist, DA dopamine agonist, QUIP-RS Questionnaire for Impulsive Compulsive Disorders in Parkinson’s Disease-Rating Scale, BIS Barratt Impulsiveness Scale, MMSE Mini Mental State Examination, HAMA Hamilton Anxiety Scale, HAMD-24 Hamilton Depression Scale-24, FAB Frontal Assessment Battery.aChi-square test.bOne-way ANOVA.cKruskal-Wallis.dMann-Whitney U.eTwo-sample t-test.*p &lt; 0.05, **p &lt; 0.01, ***p &lt; 0.001.</transformed-table></extracted-table><extracted-table><table-id>Tab2</table-id><table-label>Table 2</table-label><table-caption>VMHC differences among PD-ICD patients, PD-no ICD patients, and health controls during ON phase.</table-caption><original-table><table-wrap xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" id="Tab2"><label>Table 2</label><caption><p>VMHC differences among PD-ICD patients, PD-no ICD patients, and health controls during ON phase.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">Brain regions (AAL)</th><th rowspan="2">Number of voxels</th><th colspan="3">MNI Coordinates</th><th rowspan="2">BA</th><th rowspan="2">T Value</th></tr><tr><th>X</th><th>Y</th><th>Z</th></tr></thead><tbody><tr><td colspan="7">PD-ICD vs PD-no ICD</td></tr><tr><td>Middle frontal gyrus</td><td>18</td><td>±45</td><td>9</td><td>57</td><td>6</td><td>−3.6619</td></tr><tr><td colspan="7">PD-ICD vs HCs</td></tr><tr><td>Middle frontal gyrus</td><td>30</td><td>±45</td><td>9</td><td>57</td><td>6</td><td>−3.5509</td></tr><tr><td>Middle orbital frontal gyrus</td><td>157</td><td>±24</td><td>54</td><td>−18</td><td>11</td><td>−3.8517</td></tr><tr><td>Superior orbital frontal gyrus</td><td>42</td><td>±15</td><td>18</td><td>−18</td><td>11</td><td>−3.4832</td></tr><tr><td>Caudate</td><td>25</td><td>±12</td><td>9</td><td>6</td><td>—</td><td>−3.3566</td></tr><tr><td>Inferior frontal gyrus (pars opercularis)</td><td>66</td><td>±60</td><td>12</td><td>9</td><td>6</td><td>−3.6203</td></tr><tr><td>Middle temporal gyrus</td><td>98</td><td>±69</td><td>−30</td><td>−12</td><td>21</td><td>−4.0977</td></tr><tr><td>Superior temporal gyrus</td><td>26</td><td>±66</td><td>−27</td><td>12</td><td>22</td><td>−3.5061</td></tr><tr><td>Precental gyrus</td><td>90</td><td>±33</td><td>−21</td><td>69</td><td>6</td><td>−4.3051</td></tr><tr><td>Angular gyrus</td><td>36</td><td>±42</td><td>−69</td><td>42</td><td>7</td><td>−3.4986</td></tr><tr><td colspan="7">PD-no ICD vs HCs</td></tr><tr><td>Superior orbital frontal gyrus</td><td>92</td><td>±12</td><td>24</td><td>−24</td><td>11</td><td>−4.6984</td></tr><tr><td>Superior cerebelum</td><td>175</td><td>±33</td><td>−78</td><td>−21</td><td>19</td><td>−3.9719</td></tr><tr><td>Middle temporal gyrus</td><td>76</td><td>±57</td><td>−63</td><td>3</td><td>37</td><td>−3.4022</td></tr><tr><td>Postcentral gyrus</td><td>172</td><td>±54</td><td>−21</td><td>45</td><td>3</td><td>−3.9756</td></tr></tbody></table><table-wrap-foot><p>The resulting statistical maps were set at <italic>p</italic> &lt; 0.01 and corrected by AlphaSim. <italic>VMHC</italic> Voxel-mirrored Homotopic Connectivity, <italic>PD</italic> Parkinson’s disease, <italic>ICD</italic> Impulse control disorders, <italic>HCs</italic> healthy controls, <italic>AAL</italic> Anatomical Automatic Labeling, <italic>BA</italic> Brodmann area.</p></table-wrap-foot></table-wrap></original-table><transformed-table>Table 2<div xmlns="http://www.w3.org/1999/xhtml" class="caption">VMHC differences among PD-ICD patients, PD-no ICD patients, and health controls during ON phase.</div><div xmlns="http://www.w3.org/1999/xhtml" class="table"><table frame="hsides" rules="groups"><thead><tr><th rowspan="2">Brain regions (AAL)</th><th rowspan="2">Number of voxels</th><th colspan="3">MNI Coordinates</th><th rowspan="2">BA</th><th rowspan="2">T Value</th></tr><tr><th>X</th><th>Y</th><th>Z</th></tr></thead><tbody><tr><td colspan="7">PD-ICD vs PD-no ICD</td></tr><tr><td>Middle frontal gyrus</td><td>18</td><td>±45</td><td>9</td><td>57</td><td>6</td><td>−3.6619</td></tr><tr><td colspan="7">PD-ICD vs HCs</td></tr><tr><td>Middle frontal gyrus</td><td>30</td><td>±45</td><td>9</td><td>57</td><td>6</td><td>−3.5509</td></tr><tr><td>Middle orbital frontal gyrus</td><td>157</td><td>±24</td><td>54</td><td>−18</td><td>11</td><td>−3.8517</td></tr><tr><td>Superior orbital frontal gyrus</td><td>42</td><td>±15</td><td>18</td><td>−18</td><td>11</td><td>−3.4832</td></tr><tr><td>Caudate</td><td>25</td><td>±12</td><td>9</td><td>6</td><td>—</td><td>−3.3566</td></tr><tr><td>Inferior frontal gyrus (pars opercularis)</td><td>66</td><td>±60</td><td>12</td><td>9</td><td>6</td><td>−3.6203</td></tr><tr><td>Middle temporal gyrus</td><td>98</td><td>±69</td><td>−30</td><td>−12</td><td>21</td><td>−4.0977</td></tr><tr><td>Superior temporal gyrus</td><td>26</td><td>±66</td><td>−27</td><td>12</td><td>22</td><td>−3.5061</td></tr><tr><td>Precental gyrus</td><td>90</td><td>±33</td><td>−21</td><td>69</td><td>6</td><td>−4.3051</td></tr><tr><td>Angular gyrus</td><td>36</td><td>±42</td><td>−69</td><td>42</td><td>7</td><td>−3.4986</td></tr><tr><td colspan="7">PD-no ICD vs HCs</td></tr><tr><td>Superior orbital frontal gyrus</td><td>92</td><td>±12</td><td>24</td><td>−24</td><td>11</td><td>−4.6984</td></tr><tr><td>Superior cerebelum</td><td>175</td><td>±33</td><td>−78</td><td>−21</td><td>19</td><td>−3.9719</td></tr><tr><td>Middle temporal gyrus</td><td>76</td><td>±57</td><td>−63</td><td>3</td><td>37</td><td>−3.4022</td></tr><tr><td>Postcentral gyrus</td><td>172</td><td>±54</td><td>−21</td><td>45</td><td>3</td><td>−3.9756</td></tr></tbody></table></div>The resulting statistical maps were set at p &lt; 0.01 and corrected by AlphaSim. VMHC Voxel-mirrored Homotopic Connectivity, PD Parkinson’s disease, ICD Impulse control disorders, HCs healthy controls, AAL Anatomical Automatic Labeling, BA Brodmann area.</transformed-table></extracted-table><extracted-table><table-id>Tab3</table-id><table-label>Table 3</table-label><table-caption>ROC analyses for differentiating different groups.</table-caption><original-table><table-wrap xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" id="Tab3"><label>Table 3</label><caption><p>ROC analyses for differentiating different groups.</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Brain regions</th><th>AUC</th><th><italic>p</italic> value</th><th>95% CI</th><th>Sensitivity</th><th>Specificity</th><th>Cut-off point</th></tr></thead><tbody><tr><td colspan="7">Middle frontal gyrus</td></tr><tr><td> Separating PD-ICD from PD-no ICD</td><td>0.736</td><td>0.004<sup>**</sup></td><td>0.5954–0.8735</td><td>0.667</td><td>0.788</td><td>0.1243</td></tr><tr><td> Separating PD-ICD from HCs</td><td>0.802</td><td>&lt;0.001<sup>***</sup></td><td>0.6885–0.9151</td><td>0.702</td><td>0.810</td><td>0.2126</td></tr><tr><td> Separating PD-no ICD from HCs</td><td>0.589</td><td>0.202</td><td>0.4519–0.7258</td><td>0.568</td><td>0.697</td><td>0.2468</td></tr></tbody></table><table-wrap-foot><p><italic>ROC</italic> receiver operating characteristic, <italic>AUC</italic> area under the curve, <italic>CI</italic> confidence interval, <italic>PD</italic> Parkinson’s disease, <italic>ICD</italic> Impulse control disorders, <italic>HCs</italic> healthy controls.</p><p>*<italic>p</italic> &lt; 0.05, **<italic>p</italic> &lt; 0.01, ***<italic>p</italic> &lt; 0.001.</p></table-wrap-foot></table-wrap></original-table><transformed-table>Table 3<div xmlns="http://www.w3.org/1999/xhtml" class="caption">ROC analyses for differentiating different groups.</div><div xmlns="http://www.w3.org/1999/xhtml" class="table"><table frame="hsides" rules="groups"><thead><tr><th>Brain regions</th><th>AUC</th><th>p value</th><th>95% CI</th><th>Sensitivity</th><th>Specificity</th><th>Cut-off point</th></tr></thead><tbody><tr><td colspan="7">Middle frontal gyrus</td></tr><tr><td> Separating PD-ICD from PD-no ICD</td><td>0.736</td><td>0.004**</td><td>0.5954–0.8735</td><td>0.667</td><td>0.788</td><td>0.1243</td></tr><tr><td> Separating PD-ICD from HCs</td><td>0.802</td><td>&lt;0.001***</td><td>0.6885–0.9151</td><td>0.702</td><td>0.810</td><td>0.2126</td></tr><tr><td> Separating PD-no ICD from HCs</td><td>0.589</td><td>0.202</td><td>0.4519–0.7258</td><td>0.568</td><td>0.697</td><td>0.2468</td></tr></tbody></table></div>ROC receiver operating characteristic, AUC area under the curve, CI confidence interval, PD Parkinson’s disease, ICD Impulse control disorders, HCs healthy controls.*p &lt; 0.05, **p &lt; 0.01, ***p &lt; 0.001.</transformed-table></extracted-table></extracted-tables-set>